Malvern-based Annovis Bio plans to focus on patients who have the early form of Alzheimer’s disease in the future development of its experimental treatment for the neurodegenerative disorder, writes John George for the Philadelphia Business Journal. 

The move is based on the analysis of the mixed results from the biopharmaceutical company’s most recent study. 

Annovis is planning to implement an 18-month phase 3 clinical trial for buntanetap, its lead new drug candidate, on biomarker-positive early Alzheimer’s patients, according to Maria Maccecchini, the company’s founder and CEO. 

Phase 3 clinical trials usually represent the last hurdle that has to be successfully cleared by a drug developer before seeking final approval from the Food and Drug Administration. 

The aim of the planned clinical trial is to further validate the efficacy and safety profile for buntanetap. It will be conducted under the FDA’s guidance. 

The company is hoping that the trial will show the experimental drug can both treat the symptoms of Alzheimer’s and modify the disease. 

“Right now, most people think that’s not possible, that you either have a symptomatic drug or you have a disease-modifying drug,” said Maccecchini. 

Read more about Annovis Bio’s experimental treatment in the Philadelphia Business Journal. 

______